SFS
TBPH icon

Sowell Financial Services’s Theravance Biopharma TBPH Stock Holding History

Sowell Financial Services’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,572
Closed -$67K – 2681
2019
Q4 		$67K Buy
+2,572
New +$50K 0.01% 1050

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFS
Link Fund Solutions London, United Kingdom $157M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Sowell Financial Services's TBPH Position: Q1 2020 in Review

Sowell Financial Services sold out of Theravance Biopharma (TBPH) in Q1 2020, closing a stake of 2,572 shares — an estimated $67K sold.

Sowell Financial Services first reported a position in TBPH in Q4 2019 and held it in 1 quarter. The position peaked at $67K in Q4 2019. 105 funds tracked by Wall St. Rank hold TBPH as of Q1 2020.

  • Sowell Financial Services reported no remaining Theravance Biopharma position as of Q1 2020 after selling out during the quarter.
  • Sowell Financial Services sold 2,572 Theravance Biopharma shares in Q1 2020, an estimated $67K.
  • Sowell Financial Services first reported a position in Theravance Biopharma in Q4 2019 and held it in 1 quarter.
  • Sowell Financial Services's Theravance Biopharma position peaked at $67K in Q4 2019.
  • 105 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2020.

Based on Sowell Financial Services's 13F filing for Q1 2020, filed 12 May 2020.